Korpela Riitta, Niittynen Leena
Medical Nutrition Physiology, Pharmacology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
Microb Ecol Health Dis. 2012 Jun 18;23. doi: 10.3402/mehd.v23i0.18573. eCollection 2012.
Irritable bowel syndrome (IBS) is a major cause of abdominal discomfort and gut dysfunction worldwide. It is a poorly understood functional gastrointestinal disorder for which no effective medication is available. It is a benign condition, but its social and economic burden is significant. The symptoms consist of abdominal pain, bloating, flatulence, and irregular bowel movements. Alterations in the intestinal microbiota and mucosal inflammation may contribute to the development of IBS and probiotics could thus relieve the symptoms. This review gives an overview on the existing data on the effects of probiotics on the gastrointestinal symptoms of IBS.
A PUBMED search was made to review the relevant literature, and additional studies were obtained from the references of the selected articles.
Clinical trials suggest that certain probiotics or combinations of bacteria have beneficial effects on the IBS symptoms. However the heterogeneity of studies, e.g. suboptimal study design, inadequate number of subjects, different doses and vehicles, inadequate length, make it difficult to compare the differences between probiotics and the effect may be strain-specific.
Though evidence is very promising, no general recommendations on the use of probiotics in IBS can be given yet. Further clinical trials and data on the mechanisms of action are needed. Probiotics are considered safe and if future scientific data is able to substantiate their efficacy in IBS, they certainly could be a treatment option in relieving the symptoms in IBS.
肠易激综合征(IBS)是全球范围内腹部不适和肠道功能障碍的主要原因。它是一种了解甚少的功能性胃肠疾病,目前尚无有效的治疗药物。虽然它是一种良性疾病,但其社会和经济负担却很沉重。其症状包括腹痛、腹胀、肠胃胀气和排便不规律。肠道微生物群的改变和黏膜炎症可能导致IBS的发生,因此益生菌可能会缓解这些症状。本综述概述了关于益生菌对IBS胃肠道症状影响的现有数据。
通过检索PUBMED来回顾相关文献,并从所选文章的参考文献中获取其他研究。
临床试验表明,某些益生菌或细菌组合对IBS症状有有益影响。然而,研究的异质性,如研究设计欠佳、受试者数量不足、剂量和载体不同、研究时长不够等,使得难以比较不同益生菌之间的差异,而且其效果可能具有菌株特异性。
尽管证据很有前景,但目前还不能就IBS中使用益生菌给出一般性建议。需要进一步的临床试验以及关于其作用机制的数据。益生菌被认为是安全的,如果未来的科学数据能够证实它们对IBS的疗效,那么它们肯定可以成为缓解IBS症状的一种治疗选择。